Trial Number
303-22
Condition
Cystic Fibrosis
Participant Age Range
6 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360)”
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study.